Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Uprosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 6/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 6/20 | 1.00 |
| ▸ | PRKCB | P05771 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 5/20 | 1.00 |
| ▸ | SGK1 | O00141 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uprosertib SCHEMBL29658441 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA | |
| Uprosertib SCHEMBL18825699 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL25062541 | 0.94 | AKT1 (0.89) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL14823114 | 0.93 | AKT1 (0.87) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529493 | 0.92 | AKT1 (0.85) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529507 | 0.92 | AKT1 (0.85) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529610 | 0.91 | AKT1 (0.84) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529392 | 0.90 | AKT1 (0.81) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL22827778 | 0.89 | AKT1 (0.80) | AKT1AKT2AKT3PRKCBPRKCA | |
| SCHEMBL1529501 | 0.89 | AKT1 (1.00) | AKT1AKT2AKT3PRKCBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1771 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4720044-A1 | AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD | Beactica Therapeutics AB (SE) | 2026-04-08 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025240673-A1 | CANCER TREATMENT USING AKT INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-11-20 | — | — | WO | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| US-20140350039-A1 | COMBINATION | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | claimed |
| EP-2480084-B1 | PHARMACEUTICAL COMBINATION | GLAXOSMITHKLINE LLC (US) | 2014-11-12 | — | — | EP | claimed |
| EP-2117523-B1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2014-06-25 | — | — | EP | claimed |
| WO-2014066204-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2014-05-01 | — | — | WO | claimed |
| WO-2013160222-A1 | TREATMENT METHOD FOR STEROID RESPONSIVE DERMATOSES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-10-31 | — | — | WO | claimed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | claimed |
| US-20120322817-A1 | COMBINATION | NOVARTIS AG (CH) | 2012-12-20 | — | — | US | claimed |
| US-20120202835-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-09 | — | — | US | claimed |
| US-20120196886-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | US | claimed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | AKT1 327/4885AKT2 591/4885AKT3 709/4885 |
| US-20120322817-A1 | COMBINATION | PAICS, NUP205, DPYD | AKT1 3624/4885AKT2 3146/4885AKT3 3279/4885 |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, PI4K2A, PIK3CA | AKT1 18/4885AKT2 10/4885AKT3 39/4885 |
| US-20120202835-A1 | COMBINATION | PAICS, FOLH1, DHFR | AKT1 4281/4885AKT2 3546/4885AKT3 3945/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | AKT1 153/4885AKT2 97/4885AKT3 177/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | AKT1 6/4885AKT2 9/4885AKT3 5/4885 |
| US-20110071182-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | AKT1 2/4885AKT2 1/4885AKT3 3/4885 |
| US-20140350039-A1 | COMBINATION | PAICS, FOLH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AKT1 3664/4885AKT2 2694/4885AKT3 3247/4885 |
| US-20120196886-A1 | COMBINATION | PAICS, FOLH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AKT1 3664/4885AKT2 2694/4885AKT3 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.